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Background: Dioscorea opposita Thunb. (Huai Shan Yao, DOT), a common staple food in China, has been used for
more than 2000 years in traditional Chinese medicine (TCM) to treat different systemic diseases including
hypertension. The objective of this study was to investigate the possible antihypertensive effects of the aqueous
extract of (DOT) in renovascular hypertensive rats as well as the mechanism in reducing blood pressure.
Methods: The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in Wistar rats.
Rats with captopril, low-dose DOT and high-dose DOT treated 2K1C groups for 6 weeks. The blood pressure, cardiac
mass index (heart weight/body weight), plasma level of angiotensin-II (Ang-II), endothelin-1(ET-1), superoxide
dismutase (SOD) and malondialdehyde (MDA) were evaluated.
Results: DOT significantly reduced mean systolic and diastolic blood pressure after treatment. DOT also significantly
increased plasma SOD activity but decreased plasma MDA concentration. Renal function was improved with
captopril and DOT. DOT reduced plasma Ang-II activity and plasma ET concentration. They couldalso significantly
reduce the left ventricular hypertrophy and cardiac mass index.
Conclusions: Our results suggest that DOT may have an antihypertensive effect on hypertension by inhibit
ET-converting enzyme and antioxidant activity, which warrant further exploration.
Keywords: Antihypertensive, Dioscorea opposite Thunb, 2K1C experimental hypertension, Angiotensin-II,
Endothelin-1, HypertrophyBackground
Hypertension is the most common risk factor for myocar-
dial infarction, stroke, heart failure, arterial fibrillation,
aortic dissection and peripheral arterial diseases. It is
among the most common chronic illnesses the world faces
[1,2] and remains the leading cause of death worldwide
and one of the world’s greatest public health problems. Al-
though many new antihypertensive drugs with improved
efficacy have been introduced to the market, they still pos-
sess serious side effects. On the one hand, nutrition and
physical exercises are gaining more importance in the* Correspondence: nur818@hotmail.com; dolkunmamut@hotmail.com
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stated.treatment of hypertension. On the other hand, attention
has recently been focused on herbal and mineral prepara-
tions which are traditionally used as potential therapeutic
agents in the prevention and management of cardiovascu-
lar diseases [3-6].
Chinese yam or Shan yao comprises various species of
the genus Diascorea, which are widely cultivated in
China and their tubers are used as food as well as for
medicinal purposes. Shan yao has been considered as an
important invigorant in traditional Chinese medicine
(TCM) for many years [7]. However, the most important
variety is Dioscorea opposita Thunb. or Huai Shan Yao
in Chinese, which is used in TCM as a tonic for more
than 2000 years. It is generally believed that an intake of
the Chinese yam may be beneficial to improve the func-
tion of the spleen, stomach, kidney and lung. As a result,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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chronic diarrhea, asthma, dry cough, frequent or un-
controllable urination, diabetes and emotional instabil-
ity [8,9]. (Chinese Pharmacopoeia, 2005 edition). The
Chinese yam contains a variety of phytochemicals, in-
cluding saponins, starch, mucopolysaccharides, protein,
amino acids, mucilage, polyphenols etc. [10-13]. Modern
research showed that yam extract has many physiological
functions such as anti-diabetic, anti-hypercholesterolemia,
anti-acetaminophen-induced hepatotoxicity and nephro-
toxicity as well as antioxidant activity [12,14-17]. Interest-
ingly, the water yam (Dioscorea alata L.), another species
Shan yao has been shown to possess antihypertensive ac-
tivity in hypertensive animal models [18], suggesting that
consumption of fresh yam tubers has potential health ben-
efits for human beings. Moreover, powdered and liquid
yam products are nowadays extensively used in a variety
of food products in China and countries in the Far East.
Due to the increasing concern about the influence of foods
on health condition, we have investigated the effect of the
aqueous extract of untreated control group (DOT) on
hypertension.
Of the various experimental or genetic models of hyper-
tension, the Goldblatt chronic two-kidney, one-clip
hypertension (2K1C) is a classical model of renovascu-
lar angiotensin-II-dependent hypertension. Experimen-
tal model of renal (Goldblatt) hypertension is one of the
widely used models for the study of pathophysiology of
hypertension and antihypertensive drugs [19]. The fact
that the renin–angiotensin system (RAS) contributes crit-
ically to the pathophysiology of 2K1C Goldblatt hyperten-
sion is well established [20]. The 2K1C model, which
exhibits a transient increase in the activity of RAS and a
sustained rise in blood pressure, has been described as
very close to human mature hypertension [21,22]. Thus,
hypertension in this model is primarily the result of an
augmented total peripheral resistance and, in mild cases of
renal artery stenosis, bilateral reduction in renal-clearance
function [23]. These physiological abnormalities are prin-
cipally the result of a considerable increase in tissue and
circulating levels, and direct actions of Ang-II [24]. Evi-
dence shows that as the condition advances, the role of
Ang-II in maintaining hypertension subsides, and other
mediators become more effective in determining the level
of blood pressure [25,26]. Therefore drugs acting on RAS
are major factors in the treatment of hypertension. The
occurrence of hypertension is related to many factors. A
large number of clinical studies and animal experiments
showed that there is a close relationship between hyper-
tension and free radicals. In recent years, high blood pres-
sure and oxidative stress became a focus for researchers.
Compelling data from molecular and cellular experiments,
together with animal studies, implicate a role of oxidative
stress in hypertension [27] and thus oxidative stressinduced by reactive oxygen species (ROS) could be in-
volved in the pathogenesis of hypertension. ROS can influ-
ence vascular, renal, and cardiac function and structure by
modulating cell growth, contraction/dilatation, and in-
flammatory responses via redox-dependent signaling path-
ways. Free radicals may participate in hypertension by
damaging target organs through a variety of ways. Of the
ROS and RNS families, superoxide anion (O2
−), hydrogen
peroxide (H2O2) and NO are of major importance in the
cardiovascular and renal systems [28,29]. The generation
of ROS is a cascade of reactions initiated by the formation
of superoxide, which is rapidly dismutated to H2O2, either
spontaneously or catalyzed by the enzyme superoxide dis-
mutase (SOD) [30]. Therefore, the protection of endothe-
lial from free radical injury is very important in treating
hypertension.
So far, there is no report on the anti-hypertensive ef-
fects of DOT and the information regarding to the
mechanism of DOT against hypertension is very scarce.
For these reasons, we describe, in the present paper, the
anti-hypertensive effects of the aqueous extract of DOT,
together with changes in biological parameters such as
plasma Ang-II, ET-1, SOD activity and MDA level, fol-
lowing the administration of DOT to the renal hyperten-
sive rat model.Methods
Material
The aqueous extract of Dioscorea opposita Thunb. (DOT)
was provided by the Salome Biotechnology Co. Ltd,
Urumqi, Xinjiang, PR China. Yield for the extract is 50 g
dry extract per kg of dried Dioscorea opposita tuber. Dried
DOT was dissolved in 0.9% saline to obtain a primary so-
lution of 0.2 g/ml. The primary solution was diluted with
0.9% saline to obtain the various treatment solutions and
administered under the same volume by daily gavage.
Captopril obtained from Captopril, Sino Shanghai Shi Bao
Co. Ltd.Animals
The animals used in the present study were adult male
Sprague–Dawley rats (10–12 weeks old with body weight
180-200 g), obtained from the animal house of the Animal
Center of Xinjiang Medical University (Urumqi, Xinjiang,
PR China). The animals were housed in colony cages,
under standard laboratory conditions (12 h light, 12 h dark
cycle), with free access to standard commercial diet and
water. All experimental procedures used in the present
study were approved by the Ethics Committee of the
Xinjiang Medical University which has adopted the guide-
lines established by the Xinjiang Uighur Autonomous
Region on Animal Care and Experimentation.
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one-clip model)
The Goldblatt 2K1C model of hypertension was induced
according to the procedure described by Umar et al. [31].
Briefly, the rats were anesthetized with sodium pentobar-
bital (50 mg/kg, intraperitoneally). The left renal artery was
exposed by retroperitoneal flank incision and dissected free
of the renal vein and connective tissue. A silver clip with a
lumen of 0.22 mm was placed around the artery for partial
occlusion; in sham operations, the artery was not clipped.
After 6 weeks the systolic blood pressure (SBP) was mea-
sured using the tail-cuff method in conscious rats. Only
hypertensive rats (SBP above 150 mm Hg) were used in the
experiments.
Animal treatment
At 6 weeks after the surgery, when hypertension was
established, the 2K1C rats were divided into five groups of
10–12 rats: groups 1 - sham-operated control rats (served
as negative control); groups 2 - an untreated model group;
groups 3 - rats treated with captopril (30 mg/kg BW per
day); groups 4 - rats treated with low-dose DOT (DOT-L,
210 mg/kg BW per day); group 5- rats treated with high-
dose DOT (DOT-H, 420 mg/kg BW per day), Rats were
treated for 6 weeks with daily oral administration of the
products or the same volume of vehicle (0.9% saline)
(group 1 and group 2). Doses of DOT were chosen in ref-
erence to doses commonly used in human and doses used
in previous experiments. All rats were weighed and their
blood pressure was measured once a week for 4 weeks
(Table 1).
Measurement of blood pressure
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured by the tail-cuff method (BP-6 non-
invasive Electro-Sphygmomanometer, Chengdu Taimeng
Science and Technology, Chengdu, PR China) in awaken
rats. Each value was the average of three consecutive read-
ings. The arterial systolic and diastolic blood pressure was
measured at the weekend and continuous measurementTable 1 Cardiovascular parameters in two-kidney, one-clip Go
treatment with captopril (30 mg/kg per day), low-dose DAL (
(420mgkg/per day) (DAL-H), compared with untreated contro
Parameter Sham Model
BW (g) 572.21 ± 84.23 586 ± 110.32
HW (g) 1.46 ± 0.17 2.0 ± 0.27*
LHW (mg) 268.2 ± 0.03 396.2 ± 0.09*
HW/BW 2.55 ± 0.45 3.56 ± 0.72*
LVAWTh 0.28 ± 0.03# 0.42 ± 0.06*
Abbreviations: BW body weight, HW heart weight, HW/BW heart weight to body we
wall thickness.
Values are mean ± s.e.m.
*P < 0.05 vs. sham; #P < 0.05 vs. model; △P < 0.05 vs. captopril.was carried out three times as the average blood pressure
for weeks. Weight was measured once a week.
Measurement of left ventricular hypertrophy and cardiac
mass index
The heart and 3 cm of left ventricular hypertrophy were
removed. The cardiac mass index was the ratio of the
rat heart weight to the body weight. The left heart
weight and left ventricular anterior wall thickness were
also measured.
Assessment of the renal function
At the last week of the experiment, the animals were
placed in individual metabolic cages and acclimatized for
two consecutive days before a 24 h urine collection. Cre-
atinine and urea were measured with a commercial
enzyme-linked immunosorbent assay (WAK Chemie,
Bad Soden, Germany) as described by the manufacturer.
Determination of SOD activity and lipid peroxides
level (MDA)
Superoxide dismutase (SOD) activity and the malondialde-
hyde (MDA) level were determined according to the in-
structions on the kit (Jiancheng Institute of Biotechnology
Nanjing, China).Determination of plasma angiotensin-II and endothelin
(ET-1)concentration
After the last measurement of blood pressure, the 2K1C
rats were fasted for 12 h and anesthetized with sodium
pentobarbital (30 mg/kg BW, intraperitoneally). Blood
samples (8 ml) were taken from the abdominal aorta and
handled as follows: 4 ml were collected on aprotinin
(40 ml) and 10% EDTA disodium (30 ml), then centri-
fuged at 4°C, at 3000 r.p.m. for 10 min and the plasma
obtained was aliquoted and frozen for biochemical ana-
lysis. Plasma Ang-II and endothelin (ET-1) concentrations
were determined by using commercially available radio-
immunoassay kit (Clinical Assay, Beijing, PR China).ldblatt hypertensive rats after 6 weeks of daily oral
210 mg/kg per day) (DAL-L) and high-dose DAL
ls (model) and sham-operated rats (sham)
Captopril DAL-L DAL-H
456.21 ± 44.46# 546.21 ± 74.12△ 552.43 ± 47.87△
1.50 ± 0.17# 1.47 ± 0.22# 1.62 ± 0.19*,#,△
239.3 ± 0.02*,# 300.3 ± 0.04*,# 310.6 ± 0.03*,#,△
3.05 ± 0.44*,# 2.9 ± 0.55*,# 2.41 ± 0.38*,#,△
0.25 ± 0.03# 0.24 ± 0.04*,# 0.23 ± 0.03*,#,△
ight ratio, LHW left heart weight, LVAWTh left ventricular anterior
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The values are expressed as mean value ± standard devi-
ation (SD). The data were evaluated by using the SPSS
(version 12.0) and one-way ANOVA, followed by Bon-
ferroni t-test. Statistical significance was considered
when value of P < 0.05.
Results
DOT normalized the blood pressure of 2K1C
hypertensive rats
Untreated (model) renovascular hypertensive rats had
markedly higher SBP and DBP than the sham-operated
rats (Figure 1A). This hypertension was stable over
6 weeks of the experiment. In the captopril- and DOT-
treated groups, the blood pressure, which was initially
the same as that of the hypertensive controls, decreased
progressively over the course of the 6 weeks treatment
(P < 0.05) and there was no difference between the two
DOT dose groups (DOT-L and DOT-H). Blood pressure
was reduced by captopril to a same extent as DOT-L
and DOT-H, although it was still significantly greater
than in sham-operated rats.
DOT significantly improved left ventricular hypertrophy
and cardiac mass index in 2K1C hypertensive rats
In the DOT and captopril-treated groups, heart weight, left
heart weight, left ventricular anterior wall thickness, heart
weight/body weight ratio were lower than those of the un-
treated model group (p < 0.05). The values in the DOT
groups (DOT-H and DOT-L) were not dose dependent.
The heart weight to body weight ratio in the different dose
group for DOT (DOT-H and DOT-L) was not different
from that of the sham-operated rats (Figure 1B).
DOT improved renal dysfunction effect of 2K1C
hypertensive rats
The levels of blood urea nitrogen (BUN) and serum cre-
atinine (Scr) were significant higher in the untreated model
group than in the other group (P < 0.05). However, there
was no difference between the captopril-and DOT-treated
groups. Both DOT-L and DOT-H were able to decrease
the serum BUN and Scr levels (P < 0.05), respectively
(Figure 2).
DOT significantly regulated the antioxidant status of
2K1C hypertensive rats
The plasma SOD activity in the untreated control group
was significantly lower than that in the sham-operated
group. The SOD activity of the DOT and captopril-
treated groups was significantly higher than that in the
untreated control group (P < 0.05). The DOT and
captopril-treated groups showed significantly lower
MDA level (P < 0.05) than the untreated model group
(Figure 3A,B).DOT inhibited serum Ang-II and ACE activity of 2K1C
hypertensive rats
The changes in ET-1 and Ang-II in each group are
shown in Figure 4. Both ET-1 and Ang-II were higher in
the untreated control group than in the sham-operated
group. Both ET-1 and Ang-II in DOT-H and DOT-L
were lower than those in the untreated control group
(P < 0.05) and even lower than those in the sham-operated
group (Figure 4A,B). Ang-II level was higher in the un-
treated control group than in sham-operated group, but
returned to about the same level as in the sham-operated
group after treatment with captopril and DOT-H.
Discussion
The 2K1C renovascular hypertension is a classic animal
model of renin-dependent hypertension, which is consid-
ered to be similar to human renal hypertension. The
2K1C hypertension is an Ang-II dependent model of
hypertension where increased plasma and intrarenal Ang-
II concentrations [32,33], enhanced production and sys-
temic delivery of Ang-II by the clipped kidney, form the
basic endocrine disturbance [34]. The endothelin (ET) sys-
tem and RAS are two of the most potent vasopressor
mechanisms identified to date and in conditions where
both systems are activated, their interrelationships have
been proposed to contribute to the development of hyper-
tension [35]. Previous reports showed that blood pressure
regulation is dependent on the relationship between the
ET system and RAS [36]. The active component of the
RAS is Ang-II, which is a potent vasoconstrictor and the
mechanism of RAS-induced hypertension has generally
been attributed to the direct vasoconstrictor effects of
Ang-II and the mineralocorticoid effects of aldosterone.
Ang-II can also elevate blood pressure by augmenting nor-
adrenaline release from sympathetic nerve endings in the
vasculature [37] by increasing secretion of potent vasocon-
strictor ET-1. Besides, Ang-II is also the most potent dip-
sogen, which could induce an increase in blood volume.
On the other hand, ET-1, a major peptide primarily pro-
duced by endothelial cells, is preferentially released toward
vascular smooth muscle cells to produce sustained in-
creases in vascular tone. It is also a key factor contributing
to the extracellular volume and blood pressure homeosta-
sis. Alterations of the ET-1 system have been documented
in renal diseases in which cardiovascular disorders includ-
ing hypertension and endothelial dysfunction coexist [38].
Thus, in these pathological conditions, ET-1 has been im-
plicated in the development of hypertension, cardiovascu-
lar hypertrophy and consequently, the progressive decline
in the renal function. Previous findings suggested that the
involvement of ET-1 in the pathogenesis of hypertension
may be secondary to other factors despite the fact that
ET-1 plays a determinant role in the vascular and renal
damage. Research results demonstrated that there is a link
Figure 1 Effect of the aqueous extract of DOT on systolic (SBP), diastolic (DBP) blood pressure (A) and heart weight to body weight
ratio (B) in 2K1C hypertensive rats. Values are mean ± SD, n = 10, *P < 0.05 vs. sham; #P < 0.05 vs. model; △P < 0.05 vs. captopril.
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dogenous modulator of ET-1 production [39,40] and a
powerful stimulator of ET-1 formation in VSMCs andendothelial cells [41,42], which can further increase vascu-
lar contractile response to Ang-II. Moreover, the hyperten-
sive and renal vasoconstrictor effects together with the
Figure 2 Effect of the aqueous extract of DOT on renal function parameters in 2K1C hypertensive rats. Values are mean ± SD, n = 10,
*P < 0.05 vs. sham; #P < 0.05 vs. model.
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ET-1 [43]. Chronic infusion of suppressor doses of both
Ang-II and ET-1 was shown to induce significant increase
in SBP. The results of the present study show that DOT
could decrease hypertension in this Goldblatt 2K1C
model. The effects of high (DOT-H) and low (DOT-L)
doses were not significantly different from that of capto-
pril. Furthermore, there was no dose dependence of this
effect which could be already maximal for this extraction.
This hypertensive effect was accompanied by a significant
decrease of the plasma levels of ET-1 and Ang-II. Al-
though the ET-1 level of DOT-L and DOT-H treated
groups were found to be higher than that of captopril-
treated group, the level of Ang-II of the DOT-L group was
nearly the same as that of the captopril-treated group.
Interestingly, while DOT caused only small effect on Ang-
II, both doses of DOT (DOT-L and DOT-H) were found
to reduce significantly the ET-1 concentration to lower
values than that in the sham-operated group, being the
ET-1 value of the low dose (DOT-L) less than half of the
untreated control group. These results suggest that DOT
might act at least in part by reducing the ET release in a
manner that might be associated with the ET-converting
enzyme inhibitors. The major finding in this study is that
administration of DOT attenuated cardiac hypertrophy in
the 2K1C hypertension rats, and in combination with re-
duced blood pressure may explain an attenuation of car-
diomegaly. Since we investigated the effect of DOT on
cardiac function, we also observed the reduction in the
heart weight which indicated an improvement in cardio-
vascular function parameters. The different effect of DOT
on Ang-II and ET-1 is reflected by the effect on myocar-
dial hypertrophy which is one of the major end points inthe treatment of hypertension. Even though the values of
the SPB and DPB of the DOT-H treated group were very
similar to those of the captopril-treated group, the heart
weight to body weight ratio of the DOT-H treated group
was lower than that of the captopril-treated and the sham-
operated groups. The dissociation between the effect of
blood pressure and myocardial hypertrophy found in
DOT treated group is not surprising since this effect has
already been described [22]. Although the captopril-
treated rsts had lower absolute heart weight, left heart
weight and anterior wall thickness than the DOT-treated
rats, they also had lower body weight. Consequently, the
effect of captopril on the heart weight to body weight ratio
was higher than DOT. In addition, there was a tight linear
correlation between heart weight and blood pressure level,
indicating that the development of cardiac hypertrophy
was entirely dependent on the development of hyperten-
sion [44,45]. Inhibition of ET production which resulted
in inhibition of ET induced vasoconstriction and mitosis
can also inhibit formation of hypertension and cardiac
hypertrophy.
A recent hypothesis pointed out a possible role of oxida-
tive stress as a key player in the pathogenesis of insulin re-
sistance, cell dysfunction, and hypertension [46,47] and
many mechanisms have been implicated in processes
underlying oxidative stress-mediated hypertension. The
relationship between the development of hypertension
and the increased bioavailability of ROS or decreased anti-
oxidant capacity, or both, have been demonstrated in
many experimental models of hypertension [48] as well as
in human hypertension [49]. These findings are based, in
general, on increased levels of biomarkers of lipid peroxi-
dation and oxidative stress [50]. Experimental and clinical
Figure 3 Effect of aqueous extract of DOT on (A) plasma superoxide dismutase (SOD) and (B) plasma malondialchehyche (MDA) in
2K1C hypertensive rats. Values are mean ± SD. n = 10, * p < 0.05 vs. sham; # P < 0.05 vs. model; △P < 0.05 vs. captopril.
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festation of elevated blood pressure and this may be one
of the initiating factors promoting progression from the
pre-hypertensive stage to the hypertensive stage [51].
Research data suggest that oxidative damage and pro-
inflammatory processes may precede full-blown hyper-
tension [52]. The “ROS family” comprises many molecules
that have divergent effects on cellular function, such as
regulation of cell growth and differentiation, modula-
tion of extracellular matrix production and breakdown,
inactivation of NO, and stimulation of many kinases
and pro-inflammatory genes. Furthermore, ROS can
promote inflammation, alteration of vasomotion and ac-
tivation of matrix metalloproteinases, thus causing
platelet aggregation and stimulation of vascular smooth
muscle proliferation [53,54]. Decreased antioxidant ac-
tivity (SOD and catalase) and reduced levels of ROS
scavengers may also contribute to oxidative stress. Alarge number of clinical studies and animal experiments
indicated that there is an increase in oxidative stress
and generation of oxygen free radicals (OFR) but signifi-
cantly reduction of SOD activity in the pathophysiology
of hypertension status. A large number of OFR can cause
lipid peroxidation, thereby undermining the cell mem-
brane unsaturated fatty acids by forming lipid peroxides
(LPO). As malondialdehydes (MDA) are a class of ter-
minal lipid peroxidation metabolites, determination of
their content can directly reflect lipid peroxidation levels.
On the other hand, SOD is a natural antioxidant enzyme
which can remove superoxide anion radicals in vivo to
maintain the production of free radicals in the body and
clear the dynamic equilibrium of a metal enzyme. There-
fore, protection of the endothelial function and reduction
of free radical damage in the treatment and prevention of
hypertensive target organ damage can have a far-reaching
significance. No matter if the oxidative stress is indeed a
Figure 4 Effect of the aqueous extract of DOT on (A) plasma angiotensin-II (Ang-II) and (B) plasma endothelin-1(ET-1) concentrations
(pgml-1) in 2K1C hypertensive rats. Values are mean ± SD. n = 10,*P < 0.05 vs. sham; #P < 0.05 vs. model; △P < 0.05 vs. captopril.
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oxidative damage may result in a reduction in blood
pressure. As antioxidants are compounds that are cap-
able of trapping ROS, they may be able to reduce oxida-
tive damage, and possibly blood pressure. Our results
showed that the plasma SOD activity in the untreated
control group was lower than that in the DOT-H, DOT-
L and Captopril-treated groups. On the contrary, MDA
content in the untreated control group was significantly
higher (p < 0.05) than that of the DOT-H and DOT-L-
treated groups. The results obtained suggest that DOT
may play a key role in scavenging OFR, thus causing
anti-oxidation effects and can clear free radicals from
the system, which in turn effectively improved the
endothelial lipid oxidative damage and high blood pres-
sure to the same extent as captopril, thus guaranteeing
its therapeutic effects.Conclusion
The present study demonstrates significant antihyperten-
sive effects, which are mainly characterized by reduction
in blood pressure and prevention of left ventricular hyper-
trophy, of DOT. We hypothesized that DOT may prevent
cardiac hypertrophy by reduction of Ang-II level, inhib-
ition of E-1 production, and induction of the in vivo anti-
oxidant defense system. These findings could provide a
basicly scientific explanation to not only the widespread
use of herbal preparations derived from Dioscorea opposite
Thunb. in TCM in China but also a beneficial effect of
yam in food products which could be considered useful
information for food processing in the development of
functional food for blood pressure regulation. Neverthe-
less, further toxicological and pre-clinical studies should
be evaluated in order to warrant the therapeutic use of this
extract for combating hypertension.
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